BridgeBio Pharma, Inc. BBIO ← Back to all reports

BridgeBio Pharma, Inc.

BBIO · Healthcare
B ★★★ Hold
Nov 1, 2026 · Score 68 · Type B — Growth-style analysis Used for higher-growth companies — weighs revenue trajectory, total addressable market (TAM) expansion, and forward-looking multiples. Full methodology →
Current PriceThe market price around the time this report was written — not a live quote. The market has moved since; check a current price before acting.Methodology → $74.95
Buy ZoneThe large figure is the midpoint of the suggested buy range shown in parentheses. $67.00 ($65.00–$69.00)
Price TargetOur estimated fair value. For richly valued stocks it can sit below the current price — see Methodology.Methodology → $82.65
Expected Return
  • Target relative to the Current Price ((Target − Current) ÷ Current). Since that price is from the report date, your actual return will differ.
  • A negative Expected Return means the Price Target is below the report-date Current Price. This can occur even with a Buy or Strong Buy recommendation because recommendations follow a fixed mapping from the overall investment score, which combines business assessment, valuation and risk. This is a limitation of our score-based framework: a favorable recommendation does not always imply an attractive entry price. Consider the Price Target, Buy Zone and valuation analysis together.
Methodology →
+10.3%

Type B - BridgeBio Pharma, Inc. (BBIO) 20261101 Stock Analysis

📅 BridgeBio Pharma Key Upcoming Events

🏢 Step 1: BridgeBio Pharma Company Overview & Business Model

Q1-A1. What is BridgeBio Pharma?

Q1-A2. How Does BridgeBio Pharma Make Money?

Q1-A3. BridgeBio Pharma’s Revenue Segments & Core Income Sources

Q1-A4. Who Are BridgeBio Pharma’s Competitors?

Q1-A5. What Problem Does BridgeBio Pharma Solve?

Q1-A6. BridgeBio Pharma Key Milestones: Past 12 Months

Q1-A7. Step 1 Key Takeaways

🌲 Step 2: BridgeBio Pharma’s , Market Size & Scalability

Q2-A1. Does BridgeBio Pharma Have a Durable Economic Moat?

Q2-A2. How Big Is BridgeBio Pharma’s Market? ()

Q2-A3. How Real Is BridgeBio Pharma’s TAM? (Quality Check)

Q2-A4. Can BridgeBio Pharma Keep Expanding Its Market?

Q2-A5. Step 2 Key Takeaways

🚀 Step 3: How Fast Is BridgeBio Pharma Growing? Hyper-Growth Metrics

Q3-A1. How Fast Is BridgeBio Pharma Growing? (Revenue Trajectory)

Q3-A2. BridgeBio Pharma’s Key Growth Metrics

Q3-A3. Are BridgeBio Pharma’s Unit Economics Improving?

Q3-A4. Step 3 Key Takeaways

💪 Step 4: BridgeBio Pharma’s Profit Potential &

Q4-A1. Can BridgeBio Pharma Turn Growth Into Profit?

Q4-A2. Does BridgeBio Pharma Generate Free Cash Flow?

Q4-A3. Step 4 Key Takeaways

👔 Step 5: BridgeBio Pharma Management & Shareholder Alignment

Q5-A1. Who Leads BridgeBio Pharma? (Founder & Management)

Q5-A2. Is BridgeBio Pharma’s Management Aligned With Shareholders?

Q5-A3. Step 5 Key Takeaways

⛵ Step 6: BridgeBio Pharma Market Flow & Sentiment

Q6-A1. vs BridgeBio Pharma Guidance

Q6-A2. What Is BridgeBio Pharma’s ?

Q6-A3. Step 6 Key Takeaways

🧨 Step 7: BridgeBio Pharma Catalysts & Price Triggers

Q7-A1. What Could Re-Rate BridgeBio Pharma Stock? (Next 12 Months)

Q7-A2. BridgeBio Pharma’s Estimate Revision Trend

Q7-A3. Step 7 Key Takeaways

⚖️ Step 8: Is BridgeBio Pharma Fairly Valued? Valuation Analysis

Q8-A1. BridgeBio Pharma’s Key Valuation Multiples

Q8-A2. BridgeBio Pharma vs Peers: Valuation Comparison

Q8-A3. What Is BridgeBio Pharma Worth in the Future? (Forward Valuation)

Q8-A3-1. What Growth Hurdle Does the Market Demand From BridgeBio Pharma? (Forward Valuation Alternative)

Q8-A4. Final Valuation Adjustment

Q8-A5. Valuation Adjustment Score Calculation

💀 Step 9: What Are the Risks of BridgeBio Pharma? Fatal Risks & Pre-Mortem

Q9-A1. Is BridgeBio Pharma Burning Cash & Diluting Shareholders?

Q9-A2. Do Competition or Regulation Threaten BridgeBio Pharma?

Q9-A3. BridgeBio Pharma Pre-Mortem: What Could Go Wrong?

Q9-A4. Risk Adjustment Score

🎯 Step 10: BridgeBio Pharma Final Verdict: Score & Rating

Q10-A1. Investment Score & Rating

Q10-A2. Should You Buy BridgeBio Pharma? (Recommendation)

Q10-A3. Investment Thesis in One Line

Q10-A4. BridgeBio Pharma’s Price Trend & Key Drivers

Q10-A5. Action Plan

🕵️‍♂️ Deep Dive Analysis

Q1: Is BridgeBio Pharma’s Dependence on Attruby Its Biggest Weakness?

Q2: Can BridgeBio Pharma’s Forward Sales Valuation Be Justified by Its Rare-Disease Growth?

Q3: Can BridgeBio Pharma Sustain Attruby Growth Against Pfizer and Alnylam?

Q4: What Would FDA Approval of BBP-418 Mean for BridgeBio Pharma?

Q5: Could Oral Infigratinib Become a Competitive Achondroplasia Treatment?

Q6: Is BridgeBio Pharma’s $1.53B Liquidity Position Enough for Its Expansion?

Q7: When Could BridgeBio Pharma Reach Sustainable Operating Profitability?

Q8: How Much Does BridgeBio Pharma’s Preferred Equity Financing Affect Common Shareholders?

Q10: What Should Long-Term Investors Monitor Most Closely at BridgeBio Pharma Through 2027?

Rating History

Rating History shows the Rating assigned on each report date. Only the latest report is available to read. Scores are omitted from the timeline because reports from different periods may follow different rating scales.

  1. 2026-08-05 B
  2. 2026-08-13 B
  3. 2026-11 B